<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126043">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01870674</url>
  </required_header>
  <id_info>
    <org_study_id>YH12852-101</org_study_id>
    <nct_id>NCT01870674</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Ascending Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics(PK/PD)of
      YH12852 after oral administration in healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>the number of adverse event, seriousness of adverse event</measure>
    <time_frame>blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>significant changes in vital sign</measure>
    <time_frame>blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>significant changes in 12-lead electrocardiography</measure>
    <time_frame>blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>significantchanges in laboratory test</measure>
    <time_frame>blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>significant physical exam</measure>
    <time_frame>blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>SAD cohort: Blood and sampling during 0~48 hrs after administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacokinetics
- SAD cohort: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt</measure>
    <time_frame>SAD cohort: Blood sampling during 0~48 hrs after administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>- SAD cohort: AUCt,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet</measure>
    <time_frame>SAD cohort: Urine sampling during 0~48 hrs after administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacokinetics
- SAD cohort: Aet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>MAD cohort:Blood sampling during day1,12,13,14 ~16 after administration, urine sampling during day 1, day 14~ 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacokinetics
- MAD cohort: Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt</measure>
    <time_frame>MAD cohort:Blood sampling during day1,12,13,14 ~16 after administration, urine sampling during day 1, day 14~ 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacokinetics
- MAD cohort: AUCt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aet</measure>
    <time_frame>MAD cohort:urine sampling during day 1, day 14~ 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacokinetics
- MAD cohort: Aet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSFS</measure>
    <time_frame>SAD cohort: Day 1~7</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- SAD: BSFs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of defecation</measure>
    <time_frame>SAD cohort: Day 1~7</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- SAD: frequency of defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSFS</measure>
    <time_frame>MAD cohort: Day 1~21</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- MAD: BSFs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of defecation</measure>
    <time_frame>MAD cohort: Day 1~21</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- MAD: frequency of defecation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastic emptying lag time</measure>
    <time_frame>MAD cohort: Day 1~ 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- MAD cohort: Gastric emptying lag time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of fractional gastric emptying rate</measure>
    <time_frame>MAD cohort: Day 1 ~ 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- MAD cohort: slope of fractional gastric emptying rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic transit</measure>
    <time_frame>MAD cohort: Day 1 ~ 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>pharmacodynamics
- MAD cohort: Colonic transit</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>YH12852</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental:   YH12852
Experimental: YH12852 1mg
single dose, qd
Experimental: YH12852 3mg
single dose, qd
Experimental: YH12852 10mg
single dose, qd
Experimental: YH12852 20mg
single dose, qd
Experimental: YH12852 40mg
single dose, qd
Experimental: YH12852 60mg
single dose, qd
Experimental: YH12852 1mg
repeat dose, qd
Experimental: YH12852 3mg
repeat dose, qd
Experimental: YH12852 10mg
repeat dose, qd
Experimental: YH12852 20mg
repeat dose, qd
Each experimetal contains 12 subjects. 12 subjects were administered YH12852 x mg or active/placebo comparators.(YH12852:active:placebo=8:2:2) Additional 1 period would be processed in SAD YH12852 20mg group for observing food effect and in MAD YH12852 10mg group for bid administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852</intervention_name>
    <description>there are 6 SAD group and 4 MAD group. In each group, 8 subjects take YH12852.</description>
    <arm_group_label>YH12852</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <description>There are 6 SAD group and 4 MAD group. In each group, 2 subjects take prucalopride.</description>
    <arm_group_label>Prucalopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>There are 6 SAD group and 4 MAD group. In each group, 2 subjects take placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healty male aged 20 to 45 with body mass index(BMI) between 18 and 25kg/m2

          -  Subject who has no congential, chronic disease and disease symptoms in medical
             examination result

          -  Subject who is judged to be eligible by porincipal inverstigator or sub-investigator
             according to various reasons includiong ther abnorminal test results(clinical
             laboratory test, 12-lead ECG etc)

          -  Subjects who has signed a written informed consent voluntarily,prior to any
             porcedure, using a form that is approved by the local Institutional Review Board
             after detail explanation of the purpose, contents, and characteristic of the drug

        Exclusion Criteria:

          -  Suject who has history or presence of clinically significant diseases in liver,
             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,
             blood tumor, cardiovascular, urinary system, and mental disorder

          -  Subject who is hypersensitive to components contained in YH12852 or prucalopride or
             aspirin/antibiotics like drugs

          -  Medical history of gastrointestinal disease or acid restraining surgery, gastric/
             eshophagus surgery(excluding appendectomy, hernia surgery)

          -  Clinically significant abnormal values in dignostic check within 28 days before the
             treatment(&gt;1.25 fold of normal upper limit in the levels of AST or ALT, &gt;1.5 fold of
             normal upper limit in the levels of Total bilirubin, &lt; 80ml/min of Cockcroft-Gault
             used creatinine clearance

          -  Subject has over QTc interval of 550 ms or PR interval of 210 ms or QRS interval of
             120 ms or QT interval of 500 ms on baseline 12-lead ECG, as determined by the
             Investigator

          -  Subject who had taken usual dose of any prescription durgs within 14 days before the
             treatment  or who had used usual dose of OTC drugs within 7 days before the treatment

          -  Subject who participated in antoher clinical trail within 2 monthes before enrolling
             in this study

          -  subject who donated whole blood within 2 months or component blood within 1 month
             before the treatment

          -  Medically unacceptable contraception used during the clinical trial

          -  Subject who drank over 30g/day or were detected alcohol positive on test

          -  Subject sho stopped smoking within 3 months before the treatment or weren't able to
             stop smoking during the hospitalization

          -  Subject who had a beverage containing caffeine during the hospitalization

          -  Subjects with clinically significant observations considered as unsuitable based on
             medical judgment by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety/tolerability and pharmacokinetics/pharmacodynamics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
